Furthermore, in a real-world study including 96,128 adults with CKD and T2D, newly prescribed SGLT2i were associated with a higher risk of lower-limb amputations (HR 1.65; 95% CI 1.22–2.23) and of non-vertebral fractures (HR 1.30; 95% CI 1.03–1.65) when compared with GLP-1 RA [123]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.